NCT05301348 In Vivo Detection of Circulating Clots in Patients With Thromboembolism
| NCT ID | NCT05301348 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Arkansas |
| Condition | Thromboembolism |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-07-26 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2023-07-26 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Subjects with thromboembolic disease or at high-risk for thromboembolic conditions diagnosed with ultrasound or other standard of care techniques will be recruited to estimate the feasibility of a device to detect in vivo CBCs.
Eligibility Criteria
Inclusion Criteria * Men and women, 18 years old and older. * Evidence of current venous or arterial thromboembolic disease diagnosed by standard of care clinical, radiographic, or laboratory testing or acute ischemic stroke. * Informed consent provided by the subject. Exclusion Criteria * Pulmonary embolus with a need for mechanical ventilation or other ventilator support (may be on oxygen delivered by nasal cannula or mask at an FiO2 of ≤ 0.40) * Acute coronary syndrome (including unstable angina) * Significant cardiac arrhythmia (may have atrial fibrillation controlled with medication) * Intracardiac thrombus * Any embolus or thrombus requiring vascular surgery or interventional radiology to attempt acute embolectomy or thrombectomy * Sickle cell disease with vaso-occlusive crisis * Sepsis or life-threatening infection * Traumatic injury requiring hospitalization (within 30 days prior to enrollment) * Pregnancy or breastfeeding * Severe mental illness * Other conditions deemed by the investigators to put the subject at greater risk
Contact & Investigator
Sanjeeva Onteddu, MD
PRINCIPAL INVESTIGATOR
University of Arkansas
Frequently Asked Questions
Who can join the NCT05301348 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thromboembolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05301348 currently recruiting?
Yes, NCT05301348 is actively recruiting participants. Contact the research team at sronteddu@uams.edu for enrollment information.
Where is the NCT05301348 trial being conducted?
This trial is being conducted at Little Rock, United States.
Who is sponsoring the NCT05301348 clinical trial?
NCT05301348 is sponsored by University of Arkansas. The principal investigator is Sanjeeva Onteddu, MD at University of Arkansas. The trial plans to enroll 30 participants.